Hematology and oncology share a combined medical specialty because blood and cancer are biologically inseparable. Every blood cancer is, by definition, a disease of the cells hematologists already study, and nearly every solid tumor eventually affects the blood through clotting disorders, immune disruption, or the side effects of treatment. That overlap is not a coincidence of medical tradition; it reflects a deep biological reality that has shaped how doctors are trained, how drugs are developed, and how patients are treated.
Blood Cells Are Where Many Cancers Begin
The bone marrow is the body’s blood-cell factory. It houses stem cells that give rise to every type of blood cell: red cells that carry oxygen, white cells that fight infection, and platelets that help with clotting. These stem cells divide constantly, and because of that long lifespan and relentless self-renewal, they are particularly vulnerable to accumulating genetic errors over time. When enough mutations pile up in a stem cell, it can become what researchers call a preleukemic stem cell, the starting point of a blood cancer.
That process means leukemias, lymphomas, and myelomas are not just cancers that happen to appear in the blood. They arise directly from the normal blood-forming machinery, hijacking the same pathways hematologists spend their careers understanding.
The stem cell’s normal job is to produce offspring that gradually lose their ability to self-renew as they mature into specialized blood cells. In blood cancers, that orderly process breaks down. Cells either freeze at an immature stage and multiply uncontrollably, as in acute leukemia, or mature just enough to accumulate slowly, as in chronic leukemia. Understanding which stage of blood-cell development has gone wrong is essential for diagnosis and treatment, and that understanding sits squarely in hematology’s domain.
A Shared History Built on Leukemia
The fields did not merge by administrative fiat. Their intertwining grew organically from the earliest days of cancer treatment. In 1948, Sidney Farber and colleagues at Boston Children’s Hospital reported that a drug called aminopterin produced complete remissions in roughly a third of children with acute leukemia. That trial is widely considered one of the first successful uses of chemotherapy for any cancer.
The significance was enormous. Before Farber’s work, acute leukemia was uniformly fatal, often within weeks of diagnosis. Showing that a chemical agent could drive a blood cancer into remission opened the door to using drugs against all kinds of tumors. Meanwhile, nitrogen mustard, a chemical warfare agent repurposed for medicine, had already shown activity against lymphomas and chronic leukemias.
Because the earliest chemotherapy drugs were tested and refined in blood cancers, the doctors doing that work were hematologists. They became, almost by necessity, the first cancer specialists. When medical oncology was formally recognized as a subspecialty by the American Board of Internal Medicine in 1972, it created some tension about where hematology ended and oncology began, precisely because the two had been developing together for decades.
Why Treating Solid Tumors Requires Hematology Expertise
Even when a cancer has nothing to do with blood cells, treating it almost always affects the blood. Chemotherapy drugs are blunt instruments: they target rapidly dividing cells, and the bone marrow is one of the most actively dividing tissues in the body. The result is bone marrow suppression, a drop in blood cell production that can leave patients anemic, prone to infections, or at risk of dangerous bleeding.
Research in large groups of women with breast and ovarian cancer has quantified the scope of this problem. Patients receiving chemotherapy were roughly two to three times as likely to develop low platelet counts compared to those who did not receive it. Certain drug combinations carried strikingly high risks of aplastic anemia, a condition in which the marrow essentially stops making blood cells. A dose-response relationship was clear for several drug classes: more cycles meant more marrow damage.
Managing these complications is fundamentally hematologic work. An oncologist prescribing a chemotherapy regimen needs to understand blood counts, transfusion thresholds, growth factors that stimulate marrow recovery, and the signs of marrow failure. Separating that knowledge from the cancer treatment itself would be like asking a pilot to fly a plane without understanding the weather.
Cancer Makes the Blood Misbehave
Beyond treatment side effects, cancer itself disrupts normal blood function in ways that require hematologic expertise to manage. One of the most clinically important examples is the dramatically increased risk of blood clots. Patients with cancer face a four- to seven-fold higher risk of venous thromboembolism compared to people without cancer. This phenomenon, sometimes called Trousseau’s syndrome, involves several overlapping mechanisms: tumor cells release substances that activate the clotting cascade, they interact with platelets and the blood vessel lining, and they trigger complement activation.
The relationship between cancer and clotting is not simple. It probably represents a spectrum of disorders rather than a single process. Some cancers, particularly mucin-producing tumors of the pancreas and gut, cause a platelet-driven clotting disorder that looks different from the classic blood clot in a leg vein. Managing all of these requires someone who understands both the cancer driving the process and the blood abnormalities it creates.
Tumors can also cause bizarre effects on blood counts themselves. Certain solid tumors, like mesothelioma, occasionally produce growth factors that stimulate the marrow to churn out enormous numbers of white blood cells, a reaction called a leukemoid response. The blood picture can look so much like leukemia that distinguishing the two requires careful analysis. Figuring out whether a sky-high white count is a blood cancer or a reaction to a solid tumor is exactly the kind of problem that sits at the intersection of hematology and oncology.
Diagnostic Tools That Cross the Divide
The technologies used to diagnose and monitor blood cancers have proven valuable for solid tumors too, further blurring the line between the fields. Flow cytometry, a technique that identifies cell types by shining lasers at them and reading the light patterns, was originally developed as a workhorse for classifying leukemias and lymphomas. It can distinguish dozens of subtypes based on the proteins sitting on a cell’s surface. More recently, researchers have been exploring whether the same approach can help diagnose non-blood cancers in children, with one study showing agreement with standard diagnostic methods in over 90% of cases.
Genomic analysis has similarly transformed both fields. In blood cancers, identifying specific genetic mutations now defines entirely new disease categories. Subtypes of acute myeloid leukemia are classified by mutations in genes like RUNX1 or by the presence of specific chromosomal rearrangements. The same genomic logic applies to solid tumors, where mutations in genes like EGFR or BRAF guide treatment decisions. The sequencing pipelines, bioinformatics tools, and clinical frameworks developed for one group of cancers transfer directly to the other.
Liquid biopsy, an approach that analyzes tumor DNA circulating in the blood, represents perhaps the most literal fusion of hematology and oncology diagnostics. A simple blood draw can detect, characterize, and monitor cancers of all types. The technique matured rapidly over the past decade and is now being tested in clinical trials for both solid and blood cancers.
Drugs That Started in One Field and Jumped to the Other
Some of the most celebrated stories in cancer medicine involve drugs that were developed for a blood cancer and then turned out to work against solid tumors, or vice versa. Imatinib is the most famous example. It was designed to block a specific abnormal protein produced by a chromosomal rearrangement in chronic myeloid leukemia. By targeting that single molecular defect, imatinib turned CML from a death sentence into a manageable chronic disease.
But imatinib also inhibits other closely related proteins, including one called c-KIT. That protein drives gastrointestinal stromal tumors, a type of solid cancer that had been largely untreatable. Imatinib proved remarkably effective against those tumors as well, and it has since shown activity in other conditions driven by the same molecular targets, including a rare blood disorder called hypereosinophilic syndrome.
The imatinib story illustrates why organizing medicine around organ systems alone would be limiting. The drug’s value comes from understanding a molecular mechanism that operates across the traditional boundary between blood diseases and solid tumors. A physician trained only in hematology or only in solid tumor oncology would miss half the picture.
Stem Cell Transplants and the Hematology Infrastructure
Hematopoietic cell transplantation, commonly known as bone marrow or stem cell transplant, is one of the most intensive treatments in medicine. After more than six decades of development, it has become a standard therapy for blood cancers and other serious blood disorders that would otherwise be fatal.
The procedure works by replacing a patient’s diseased or destroyed marrow with healthy stem cells, either from a donor or from the patient’s own body after collection and storage. It requires deep expertise in blood-cell biology, immune-system management, infection control, and the dozens of complications that can arise when one person’s immune cells take up residence in another person’s body.
Transplant programs are staffed primarily by hematologist-oncologists, and the infrastructure they require, including blood banks, apheresis units, and specialized laboratories, serves both blood cancer patients and those with solid tumors who need marrow support after aggressive chemotherapy. This shared clinical infrastructure is another practical reason the fields remain joined.
CAR-T Therapy and the Blood Cancer Proving Ground
Immunotherapy, the use of the body’s own immune system to fight cancer, has been one of the biggest advances in oncology over the past two decades. One of the most dramatic forms is CAR-T cell therapy, in which a patient’s own immune cells are extracted, genetically engineered to recognize cancer, and infused back into the body. To date, the U.S. Food and Drug Administration has approved seven CAR-T therapies, all of them for blood cancers targeting proteins called CD19 and B-cell maturation antigen.
The reason CAR-T has succeeded first in blood cancers is instructive. Blood cancer cells circulate freely or cluster in accessible locations like the bone marrow and lymph nodes, making them relatively easy targets for engineered immune cells. They also tend to display uniform surface proteins that the CAR-T cells can lock onto. Solid tumors present a much harder problem: they hide behind physical barriers, create hostile microenvironments that suppress immune cells, and display a patchwork of surface markers that vary from cell to cell within the same tumor.
No CAR-T therapy has been approved for solid tumors despite extensive research, and the challenges are substantial. But the foundational work, the manufacturing processes, the management of side effects like cytokine-release syndrome and neurotoxicity, all of this expertise was built within hematology-oncology programs treating blood cancers. If CAR-T or related therapies eventually crack the solid tumor problem, it will be because of knowledge gained from blood cancer patients first.
Non-Malignant Blood Disorders in Cancer Patients
A substantial part of a hematologist-oncologist’s workload involves blood problems that are not themselves cancerous. Disseminated intravascular coagulation, a dangerous condition where the clotting system goes haywire throughout the body, appears in up to a third of critically ill patients with sepsis. But it is also triggered by cancer itself, making it a regular problem on oncology wards.
Anemia from chronic disease, iron deficiency caused by cancer-related bleeding, immune-mediated destruction of blood cells by tumors, and drug-induced platelet disorders all fall into this category. A cancer patient presenting with unexplained bleeding or a dropping blood count needs someone who can quickly determine whether the problem is the cancer, the treatment, or an independent blood disorder. That diagnostic process draws on hematology training even when the underlying disease is purely oncologic.
Genomics Is Making the Overlap Even Deeper
The genomic revolution has, if anything, made hematology and oncology more intertwined rather than less. As researchers catalog the mutations driving different cancers, they keep finding that the same genes and pathways appear in both blood and solid tumors. A mutation in a gene that regulates cell growth might cause leukemia in one context and a brain tumor in another. The treatment implications often follow the mutation rather than the organ.
This has given rise to what some call “tumor-agnostic” therapy, where a drug is approved based on the molecular target it hits rather than where in the body the cancer grows. The practical effect is that hematologists increasingly need to understand solid tumor biology, and solid tumor oncologists increasingly need to understand blood-cell biology, because the molecular logic is shared.
The Training Model and Whether It Might Change
In the United States, most physicians who specialize in either blood disorders or cancer do so through a combined hematology-oncology fellowship after completing internal medicine residency. The training covers both fields over roughly three years. This model has worked well for decades, but it is under increasing strain.
The volume of knowledge in each field has exploded. New drug approvals, genomic subtypes, immunotherapy regimens, and supportive care protocols have multiplied to the point where no single physician can master everything. Some training programs and professional commentators are now calling for career-aligned specialization tracks within the combined fellowship, allowing trainees to develop deeper expertise in either hematology or oncology while preserving enough foundational breadth to handle the overlap.
The push for reform acknowledges a tension that has existed since the 1972 recognition of medical oncology as its own subspecialty: the two fields are biologically inseparable but practically enormous. Some academic medical centers already have separate hematology and oncology divisions, with specialists who focus exclusively on one or the other. Community practices, by contrast, often have a single hematologist-oncologist handling everything from sickle cell disease to lung cancer to lymphoma, because that is what the patient population requires.
Access Gaps and Why Integration Matters for Patients
The combined specialty has practical implications for patient access, particularly in parts of the world where specialists are scarce. In underserved regions, a physician trained in both hematology and oncology can manage a wider range of conditions than someone trained in only one. This matters because delayed diagnosis and limited access to effective therapies lead to poorer survival outcomes, especially for older adults with leukemia and other blood cancers.
Recent therapeutic advances, including targeted oral therapies and lower-intensity treatment regimens, have improved survival and quality of life for older cancer patients in wealthier countries. But those benefits have not reached many parts of the world due to economic, infrastructure, and policy barriers.
Patients with blood cancers also carry a heavy symptom burden that bridges the two fields. Research on patients with acute leukemia has found that they report a median of nine physical and two psychological symptoms. Those with intense fatigue, sleep problems, and pain were significantly more likely to also report intense worry and sadness. Yet referrals for specialized symptom management were strikingly low: no patients with moderate-to-severe pain were referred for specialized pain control, and only about one in eight of those with severe psychological distress saw a mental health professional within a month. That kind of gap suggests the combined specialty still has room to grow in integrating supportive care alongside disease-directed treatment.
Orphan Drugs and the Economics of Rare Blood Cancers
The financial and regulatory landscape also keeps the fields linked. Many blood cancers are individually rare, which qualifies them for orphan drug status under U.S. law. Since the Orphan Drug Act was passed in 1983, over a third of all approved orphan drugs have been for cancer, with hematologic malignancies and solid tumors together accounting for the majority of those approvals. The economic incentives that drive drug development for rare diseases frequently produce treatments that cross the hematology-oncology boundary, as companies develop drugs for a rare blood cancer and then test them against solid tumors sharing the same molecular target, or the reverse.
This cross-pollination of drug development reinforces the practical case for keeping the fields together. A drug discovered for myeloma might end up being tested in breast cancer. A checkpoint inhibitor developed for melanoma might prove effective in Hodgkin lymphoma. The physicians evaluating these drugs in clinical trials, prescribing them to patients, and managing their side effects need fluency in both worlds.